Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONeeR: Precision Immuno-Oncology for PD-1/PD-L1 ICI-resistant NSCLC
2018-000914-39Phase 2Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Aug 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: 12-week Disease Control Rate. Started Aug 2018; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000914-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000914-39.